Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
A modular strategy for the repair of critical sized bone fractures (HEALIKICK)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Spain,Germany,Spain,Spain,United Kingdom
Call: Regenerative medicine: from new insights to new applications (H2020-SC1-2019-Single-Stage-RTD, 2019)
Start date: 2020-06-01
End date: 2025-05-31
Duration (months): 60.0
Total project cost (EUR): 5243535.5
EU funding (EUR): 5243535.5
Participants: 6
Project status: SIGNED

Disruptive technologies for bone regeneration must be able to tackle complex fracture environments which have developed into non-union bone defects. These types of fracture are common and increasingly prevalent when considering the rise in osteoporosis cases. Bioengineered bone graft systems need to be able to guide the regrowth of new bone into substantial voids and therefore implants pre-seeded with mineralising cells are of significant clinical interest. We will implement a surgical co-administration of two robust technologies 1) a granular graft material with a highly osteogenic coating that presents relevant biologics very efficiently and 2) pre-differentiated osteogenic adipose mesenchymal stromal cells (MSCs) that together will underpin efficient bone regeneration. Within the project we aim to take these two technologies into GMP and ISO rated manufacture as required for any clinical therapy. We will then implement these therapies in pre-clinical studies to obtain efficacy and safety data to support a full clinical trial application. The novel technologies will be developed into a new medical device and a new cellular therapy with pre-clinical validation for their co-administration. This modular application of two highly advanced therapies is itself highly novel in terms of clinical strategy and by the end of the project we aim to have made the required regulatory and technical developments to submit them for clinical trial. In parallel to the core therapy we will expand the therapeutic pipeline by replacing the granular graft with 3D printed polymeric scaffold, again including including a highly osteogeneic coating, as a carrier for the cell therapy. Targeting even larger bone defects, this scaffold will be co-administered with the cellular therapy in pre-clinical efficacy studies.

Keywords: growth factors,implant coating,medical device,cell engineering,bone
Integrating 5G enabling technologies in a holistic service to physical layer 5G system platform (Int5Gent)

Framework: Horizon 2020 — Industrial Leadership
Programme: Information and Communication Technologies
Action type: Innovation actions
Partnership: 5G PPP (cPPP)
Countries involved: Spain,Israel,Spain,Italy,Greece,Greece,Sweden,Belgium,Greece,Slovenia,Luxembourg
Call: 5G PPP – 5G core technologies innovation (H2020-ICT-2020-1, 2020)
Start date: 2020-11-01
End date: 2023-10-31
Duration (months): 36.0
Total project cost (EUR): 7447658.75
EU funding (EUR): 5948029.88
Participants: 16
Project status: SIGNED

Int5Gent targets the integration of innovative data plane technology building blocks under a flexible 5G network resource, slice and application orchestration framework, providing a complete 5G system platform for the validation of advance 5G services and IoT solutions. The project builds upon a suite of innovative 5G technological solutions spanning hardware, software, and networking systems that have been conceptualized and developed under the latest 5GPPP initiative projects and are now taken to TRL-7 and above. It also combines novel and state-of-the-art solutions able to further upgrade the capabilities and maturity level of cutting-edge 5G core technologies enabling the creation of an innovative 5G ecosystem. A sample of the developed and offered technologies include flexible multi-RAT baseband signal processing, beam steering, mmWave technology solutions at 60GHz and 150GHz bands, hardware-based edge processor with TSN, GPU processing capabilities, innovative 5G terminals and elastic SDN-based photonic data transport. The integration of the technology blocks is performed as part of an overall 5G architecture that promotes edge processing and is orchestrated by an NFVO compatible framework with edge node extensions at the network layer and an overlay vertical services application orchestrator at the user plane layer. The overall platform is implemented in two extended testbeds which include actual field deployed segments and managed by the network operators of the consortium. The validation and showcasing testbeds host 3 use case scenarios covering the deployment of services related to multiple vertical sectors as well as innovative applications for smart IoT networked devices. The use cases are designed in order to highlight the benefits of the adopted technologies in terms of increased bandwidth, low latency and high reliability and create new markets opportunities especially for the participating SMEs through pilot validation of their offered solutions.

Keywords: mobile edge computing mec,software defined networking,virtualization,thz transceivers,mmwav,edge nodes
Secondary prEvention of CardiovascUlaR disease in the Elderly trial (SECURE)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Treating and managing disease
Action type: Research and Innovation actions
Countries involved: Germany,Spain,Spain,Italy,Hungary,Poland,France,France,Czechia,United Kingdom
Call: Comparing the effectiveness of existing healthcare interventions in the elderly (H2020-PHC-2014-two-stage, 2014)
Start date: 2015-05-01
End date: 2021-12-31
Duration (months): 80.0
Total project cost (EUR): 6898301.5
EU funding (EUR): 5998786.0
Participants: 12
Project status: CLOSED

While Cardiovascular diseases (CVD) are the main cause of death worldwide, they are responsible for half of all deaths in Europe. The overall ageing of the European population and improving survival of patients with coronary heart disease has created a large population of older adults eligible for secondary prevention. Despite the established efficacy of cardiovascular medications, suboptimal adherence reduces their effectiveness and is the primary reason for suboptimal clinical benefit, contributing significantly to worsening of diseases and deaths at the population level. SECURE will be the first trial testing the efficacy of a fixed dose combination (FDC) polypill for secondary cardiovascular prevention in the elderly population (≥ 65 years old). The main objective is to evaluate the potential benefit of the FDC as a component of a cost-effective, globally available and comprehensive treatment strategy for secondary prevention of cardiovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke, and hospitalisation requiring revascularisation) as compared to standard therapy (the three components of the polypill given separately). As part of the secondary endpoints, SECURE will compare the effect of both strategies on adherence and intermediate measures of risk factor control such as lipids and blood pressure. Importantly, it will also measure the pharmacoeconomic impact of the FDC intervention as well as regional differences in all outcomes. The five-year project will thus involve subjects from seven different countries: Spain, Italy, France, Germany, Hungary, Poland and the Czech Republic. The findings and conclusions obtained in SECURE will allow the drafting of clinical guidelines and recommendations that will provide useful guidance and will serve as a reference framework for all stakeholders involved in tackling major challenges related to secondary prevention and treatment of chronic diseases in the elderly population.

Keywords: polypill,secondary cardiovascular prevention,cost effectiveness,medication adherence,myocardial infarction,coronary artery disease,fixed dose combination,elderly,clinical trial
Fulfilling the Potential of Globular Clusters as Tracers of Cosmological Mass Assembly (Multi-Pop)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Universe sciences
Panel description: Astro-physics/-chemistry/-biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: United Kingdom
Call: ERC Consolidator Grant (ERC-2014-CoG, 2014)
Start date: 2015-09-01
End date: 2021-08-31
Duration (months): 72.0
Total project cost (EUR): 1429439.0
EU funding (EUR): 1429439.0
Participants: 1
Project status: CLOSED

Globular clusters (GCs) are among the oldest luminous sources in the universe, bearing witness to the earliest stages of galaxy formation as well as their evolution to the present day. While GCs have played a pivotal role in our understanding of the assembly of galaxies, their full potential remains unfulfilled due to our lack of understanding of how they form. One of the largest stumbling blocks has been the anomalous chemistry (both metallicity distributions and abundance patterns) of GCs relative to field stars within galaxy. Here, we will turn the problem around and exploit these differences to understand the co-evolution of GCs and their host galaxies. Our understanding of GCs and their formation has undergone a radical change in the past two decades. First, it is now clear that while traditionally thought of as the quintessential simple stellar populations (i.e., all stars within a cluster have the same chemical abundances and age), globular clusters host multiple stellar populations with spreads in He, many light elements (e.g., Na, O, Al) and even Fe in a few cases. Secondly, GCs, once thought to only be able to form in the special conditions present in the early Universe, are now known to be still forming today (known as Young Massive Clusters - YMCS). These two facts have opened up a new window into the interconnectedness of GC and galaxy formation and co-evolution. In this project we will quantitatively test current GC formation models with observations of YMCs, as well as organise what is known of the stellar populations within GCs (e.g., abundance spreads, CMD morphologies), providing, for the first time, a global view (i.e., which characteristics are specific to individual GCs and which are common to all GCs). These results, when combined with what is known about massive cluster formation in the local universe, will provide an unprecedented opportunity to use GCs to constrain the hierarchical assembly of galaxies.
Readout of DNA methylation (ReaDMe)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Integrative Biology: from Genes and Genomes to Systems
Panel description: Genetics, epigenetics, genomics and other ‘omics studies, bioinformatics, systems biology, genetic diseases, gene editing, innovative methods and modelling, ‘omics for personalised medicine
Countries involved: Switzerland
Call: ERC Advanced Grant (ERC-2014-ADG, 2014)
Start date: 2016-01-01
End date: 2020-12-31
Duration (months): 60.0
Total project cost (EUR): 2136969.0
EU funding (EUR): 2136969.0
Participants: 1
Project status: CLOSED

DNA and chromatin modifications are essential for proper control of gene expression during development. How these marks alter transcriptional programs and modulate binding patterns of sequence specific transcription factors (TF) remains poorly understood. This currently limits our interpretation of epigenomic maps towards their incorporation into predictive models of gene regulation. ReaDMe has the ambitious goal to systematically define the sensitivity of TFs to local levels of DNA methylation in vivo. We will use a combination of genomics, genome editing and proteomics tools to comprehensively identify transcriptional regulators that respond to DNA methylation. As a first approach, we will interrogate changes in the global TF binding landscape when DNA methylation is ablated from the genome. Using both embryonic stem cells and somatic cells, these experiments are aimed at identifying sites that are occupied by TFs in a DNA methylation dependent manner within different cellular context. Secondly, we will combine parallelized chromosomal insertions with targeted footprinting to determine the link between DNA sequence context, methylation density and TF binding. In a third approach we will define the global chromatin proteome as a function of DNA methylation. Through the use of a novel and orthogonal proteomics assay, we will characterize DNA methylation sensitive changes in the chromatin-bound proteome. Candidate factors predicted from all approaches will be validated and functionally characterized through direct genome-wide mapping as well as loss of function analysis. ERC funding would enable ReaDMe to develop an integrated setup to in vivo identify and characterize where DNA methylation influences the cis-regulatory landscape by modulating binding profiles of trans-acting factors. This goal represents a crucial step towards comprehensive understanding of the genomic readout of DNA methylation and its impact on gene regulation.

Keywords: dna methylation,transcription factor,genome engineering
Innovative Business Models for a new Integrated Rapid Microbial Pathogen Tester (RapidBact)

Framework: Horizon 2020 — Societal Challenges
Programme: Europe in a changing world - inclusive, innovative and reflective societies
Action type: SME instrument
Countries involved: United Kingdom
Call: SME business model innovation (H2020-SMEINST-1-2015, 2015)
Start date: 2016-02-01
End date: 2016-07-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

DelAgua Water Testing currently retails and distributes water testing equipment and consumables to over 150 countries globally. Our client base includes private, public sector and significant numbers of non-governmental organizations. DelAgua is researching an innovative, rapid, microbiological pathogen water test for field use in routine monitoring, surveillance and disaster relief situations. This test will identify bacterial species, their viability and numbers present in less than 2 hours. User feedback has indicated that the device must meet the following criteria: • Simple to use • Portable • Rugged • No need for mains power • Have an automated means of recording and analysing results Current test equipment offers a choice between rapid absence/ presence indicators with no quantification; or tests which offer quantification and specificity but with significant process time (from 18 hours to several days) for a result. There is real demand for this new rapid test which will have applications globally for the testing of drinking water and more widely irrigation, bathing and recreational waters, and water/wastewater treatment plants under private and public management. Unique features of our new test offer an opportunity to go beyond our current retail and distribution model. We wish to test radically innovative business models which could offer greater value and flexibility to both DelAgua and its customers. We believe a different model could open entirely new markets and impact on the health of millions of people worldwide through the provision of near real time regional water safety monitoring systems, something never before achieved. A European supply chain will be created to manufacture both the hardware and consumables and DelAgua will create R&D facilities and jobs to support the new test. If successful this project will help drive Europe's growth and global competitiveness and reinforce Europe's contribution to global healthcare solutions.

Keywords: water global pathogen testing
Assessing transcriptional and nuclear pore aging in age-equivalent and rejuvenated induced neurons from Alzheimer patients (iNtoPoreAge)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Reintegration panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Austria
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2019-08-01
End date: 2023-01-29
Duration (months): 24.0
Total project cost (EUR): 178156.8
EU funding (EUR): 178156.8
Participants: 1
Project status: SIGNED

I am a stem cell biologist specialized on modeling human neurodegenerative diseases. During my PhD with Dr. O. Brüstle (University of Bonn), I was trained in human stem cell and reprogramming technologies working on human models for Alzheimer’s Disease (AD). As a postdoc at the Salk Institute with Dr. F. H. Gage, I acquired and strong foundation in functional neuroscience, nuclear pore biology and systems biology/bioinformatics. My work helped to better understand complex neuropsychiatric disorders, as well as the process of neuronal aging. I could show that direct conversion of human fibroblasts into induced neurons (iN) preserves signatures of cell aging, while iPSC reprogramming erases them. To start my own independent lab, I have accepted a tenure track position at the University of Innsbruck. As an independent scientist, I seek to bring together my recent findings on reprogramming and aging, my permanent interest in AD, and powerful systems biology and bioinformatics to unravel the age-dependent disease-initiating mechanisms of sporadic AD. In this proposal, I, together with my supervisor Prof. Dr. Frank Edenhofer, designed a dedicated research and training plan. In the first aim of the project, I will generate phenotypically old (iN) and rejuvenated (iPSC) neurons from an established set of well-characterized AD patients and controls. Using unbiased transcriptome approaches, the data will help to better understand the impact of neuronal aging on sporadic AD pathogenesis. In a second aim, I will use live-cell imaging approaches to study the age-related dysregulation of nucleo-cytoplasmic transport. The goal is to better understand how cellular aging affects pathogenesis, in order to pinpoint the earliest and potentially most treatable mechanisms involved in AD. This award will enable my research in Innsbruck and give me protected time to successfully complete the proposed research, which is vital for establishing myself as an independent researcher in Europe.

Keywords: nuclear pore,disease modeling,aging
Competitive Advantage for the Data-driven ENTerprise (CADENT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Norway
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-07-01
End date: 2018-06-30
Duration (months): 24.0
Total project cost (EUR): 196400.4
EU funding (EUR): 196400.4
Participants: 1
Project status: CLOSED

The notion of big data and its application in driving organizational decision making has attracted enormous attention over the past couple of years. Prominent examples of companies engaging in the big data paradigm have illustrated the potential in generating substantial business impacts and fundamentally changing the way organizational-level decisions are made. The need to harness the potential of rapidly expanding data volume, velocity, and variety, has seen a significant evolution of techniques and technologies for data storage, management, analysis, and visualization. Yet, there is limited understanding of how organizations need to change to embrace these technological innovations and the business shifts they entail. The purpose of CADENT is to examine how big data is successfully exploited and by which means it improves competitive performance. The aim is to identify the critical success factors in a range of contexts, and use these findings to promote research and practice. More specifically, the proposed research project is targeted in identifying and categorizing the primary decisions needs from big data intelligence and analytics in varying industries and for different strategic orientations. The goal is to develop a clear understanding of how strategy and context shape data-driven information requirements, and explore through a holistic approach the human, technological, managerial, and relational aspects that contribute to successful data-driven decisions. In effect, the CADENT project seeks to explore through case studies, action research, as well as qualitative and quantitative methods how big data is optimally exploited and the organizational changes it creates. Implications stemming from the CADENT project will serve industry by providing a set of guidelines for companies adopting big data strategies to optimally exploit their investments and gain a competitive edge.
IRON CHELATOR NBMI FOR THE TREATMENT OF IRON OVERLOAD IN BETA-THALASSEMIA MAJOR (Chelator)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Ireland
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2019-06-01
End date: 2020-04-30
Duration (months): 11.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

β-thalassemia major (βTM) is a lethal orphan disease with genetic background, diagnosed in infancy and requiring recurrent blood transfusions to prevent malformations, assure acceptable quality of life and prolong patient’s lifetime. Constant transfusions are related to severe adverse effects due to the resultant iron overload, including severe impairment of internal organs’ function and heart disease, with cardiac complications causing over two thirds of deaths in βTM patients. Life-long, effective iron chelation therapy is the only measure to reduce these risks, but available chelators have low efficacy and tolerability and/or complicated administration route. Together with high costs it hampers compliance, reducing the efficacy of available chelators even more and leaving unmet the need for safe, effective and easy to use iron chelator. Emeramide is an efficient metal chelator shown to decrease iron levels in vitro and in vivo, with a huge advantage of safety already confirmed in clinical trials up to Phase 2a. The drug has been recognized by the US and the EU authorities and received Orphan Drug Designation for mercury toxicity treatment. Thanks to its great tolerability Emeramide promotes high compliance with chelation therapy, making patients’ lives not only longer, but also as close to normal as possible.

Keywords: iron overload,iron chelator,thalassemia,emeramide